According to a corporate announcement, CHINARES PHARMA (03320) disclosed the financial results for Tasly Pharmaceutical Group Co.,Ltd. for the first half of 2026.

The company reported operating revenue of RMB4.201 billion, representing a year-on-year decrease of 2.03%. This decline was primarily attributed to an overall downturn in the traditional Chinese medicine injection sector and a reduction in sales revenue from cold and fever medications compared to the same period last year.

Net profit attributable to shareholders of the listed company reached RMB893 million, marking a 15.23% increase compared to the prior year period.

Adjusted net profit attributable to shareholders, which excludes non-recurring gains and losses, amounted to RMB871 million, reflecting a significant year-on-year growth of 36.01%.